Biotechnology companies Cell Culture Service (CCS) and Cytocentrics AG have signed a research and licence agreement.
The cooperation's aim is to develop electrophysiologically optimised ion channel cell lines that allow a reliable testing of substances and drugs.
The pharmaceutical industry depends on suitable in-vitro test methods for preclinical drug screening and safety pharmacology testing.
The automated patch clamp technology has established itself in this field, but in many cases the application of conventional recombinant cell lines results in low data quality.
The cooperation paves the way for the production of cell lines generating reliable and reproducible data in automated patch clamp systems.
CCS will produce recombinant cell lines and Cytocentrics will focus on electrophysiological optimisation.
Each batch of cells is subjected to quality controls prior to delivery.
Quality standards refer to the seal rate, rate of whole-cell recordings, stability and existence of a homogenous flow.
Customers can either acquire a licence for a cell line or order Instant Cells, rendering the time consuming cultivation of cells unnecessary.
These cells are ready-to-use in an assay 15 minutes after defrosting.
